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Escherichia coli MsbA, the proposed inner membrane
lipid flippase, is an essential ATP-binding cassette
transporter protein with homology to mammalian multidrug resistance proteins. Depletion or loss of function
of MsbA results in the accumulation of lipopolysaccharide and phospholipids in the inner membrane of E. coli.
MsbA modified with an N-terminal hexahistidine tag
was overexpressed, solubilized with a nonionic detergent, and purified by nickel affinity chromatography to
⬃95% purity. The ATPase activity of the purified protein
was stimulated by phospholipids. When reconstituted
into liposomes prepared from E. coli phospholipids,
MsbA displayed an apparent Km of 878 M and a Vmax of
37 nmol/min/mg for ATP hydrolysis in the presence of 10
mM Mg2ⴙ. Preincubation of MsbA-containing liposomes
with 3-deoxy-D-mannooctulosonic acid (Kdo)2-lipid A increased the ATPase activity 4 –5-fold, with half-maximal
stimulation seen at 21 M Kdo2-lipid A. Addition of Kdo2lipid A increased the Vmax to 154 nmol/min/mg and decreased the Km to 379 M. Stimulation was only seen
with hexaacylated lipid A species and not with precursors, such as diacylated lipid X or tetraacylated lipid
IVA. MsbA containing the A270T substitution, which renders cells temperature-sensitive for growth and lipid
export, displayed ATPase activity similar to that of the
wild type protein at 30 °C but was significantly reduced
at 42 °C. These results provide the first in vitro evidence
that MsbA is a lipid-activated ATPase and that hexaacylated lipid A is an especially potent activator.

The envelope of Escherichia coli and other Gram-negative
bacteria consists of an inner membrane, a periplasmic space,
and an outer membrane (1). The outer leaflet of the outer
membrane is composed of lipopolysaccharide (LPS),1 a complex
glycolipid that is essential for an effective permeability barrier
and is a potent stimulator of the innate immune system in
mammals (2–5). Lipid A is the hydrophobic anchor of LPS
(2–5). Lipid A biosynthesis is essential for survival of most
Gram-negative bacteria and is a target for the design of new
antibiotics (5–9).
The enzymes that catalyze the synthesis of Kdo2-lipid A, the
minimal lipid A required for survival in laboratory strains of
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E. coli, are cytoplasmic or associated with the inner membrane
(2, 3, 5). The mechanism by which E. coli transports newly
synthesized lipid A from its site of biosynthesis at the inner
face of the inner membrane to the outer membrane is not fully
understood. Recent studies from our laboratory have demonstrated that export of both lipid A and glycerophospholipids
requires the inner membrane protein MsbA (10, 11), originally
identified as a multicopy suppressor of the temperature-sensitive growth phenotype of lpxL(htrB) knockouts (12), a gene
encoding a key late acyltransferase in the lipid A biosynthetic
pathway (13, 14) (Fig. 1A). MsbA is a member of the ATPbinding cassette (ABC) superfamily, is closely related to mammalian multidrug-resistance (MDR) proteins, and is required
for growth of E. coli (12, 15). Zhou et al. (10) demonstrated that
depletion of cellular MsbA resulted in the gradual accumulation of lipid A and glycerophospholipids in the inner membrane. More recently, we have isolated a novel, temperaturesensitive E. coli point mutant of MsbA (designated WD2) and
have shown that loss of MsbA function results in rapid cessation of cell growth, accompanied by accumulation of lipid A and
phospholipids in the inner membrane and formation of inner
membrane invaginations visible by electron microscopy (11).
MsbA in WD2 contains a single amino acid substitution
(A270T) located in its fifth transmembrane span (Fig. 1B). Our
genetic evidence strongly suggests that MsbA functions as a
general lipid transporter, or flippase, playing a key role in the
movement of lipids from the inner membrane to the outer
membrane of E. coli (11). Although there is no evidence that
MsbA confers multidrug resistance in E. coli, the related LmrA
protein of Lactococcus lactis does in fact confer resistance to
many of the same amphiphilic compounds that are transported
by MDR1 (16, 17).
E. coli msbA encodes a 584-amino acid residue inner membrane protein (11, 12). It was predicted to contain a classical
ABC domain at its C terminus and a hydrophobic region at its
N terminus, consisting of six transmembrane spans (11, 12).
The proposed topology and dimeric structure of MsbA were
validated recently by the crystal structure (18) at 4.5 Å resolution (Fig. 1B). MsbA contains an intriguing cleft, oriented
toward the cytoplasm, between its two subunits (Fig. 1B) (18).
The cleft is lined with basic amino acids, and it is sufficient in
size to accommodate lipid A or several glycerophospholipid
molecules (18). ATP binding and hydrolysis presumably drive
a conformational change that results in lipid extrusion to
the periplasmic surface of the inner membrane (Fig. 1) (18).
The A270T substitution is situated at a critical site near the
periplasmic surface in the MsbA molecule (Fig. 1B), consistent
with the lipid transport defect seen in WD2 at 42 °C.
Previous studies have shown that the intrinsic ATPase activity of MDR proteins and other ABC transporters, when
purified and reconstituted into liposomes, can be stimulated by
physiologic concentrations of transported substrates (19 –23).
To develop functional assays for MsbA and to elucidate its role
in lipid export, we have expressed the protein as an N-terminal
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FIG. 1. Proposed role of E. coli MsbA in phospholipid export
and structure of the E. coli MsbA dimer at 4.5 Å resolution. A,
after the MsbA mediated flip-flop/transport of newly made hexaacylated lipid A and phospholipids at the inner membrane (11), additional
proteins are likely to be involved in steps 2 and 3, but these have not yet
been identified. B, this backbone tracing of MsbA was made from
Protein Data Bank file 1JSQ (18). Transmembrane helices 1– 6 are
colored purple, blue, yellow, green, red, and orange, respectively. The
intracellular domain (ICD) is brown, and the nucleotide binding domain
(NBD) is cyan (18). A schematic model of lipid A is shown for size
comparison. The location of the Ala-270 residue, which is changed to
threonine in the temperature-sensitive lipid transport mutant WD2
(11), is shown as a red sphere. The putative chamber for the binding of
lipids on the inner surface of the inner membrane (18) is lined with
basic residues (not shown).

hexahistidine fusion, purified it to near homogeneity, and reconstituted it into liposomes. The ATPase activity of purified
MsbA is dependent upon the presence of phospholipids and is
stimulated further by Kdo2-lipid A.
EXPERIMENTAL PROCEDURES

Materials—LDAO was purchased from Fluka Biochemika. DDM was
purchased from Sigma. E. coli phospholipids were purchased from
Avanti Polar Lipids, Inc. Bio-Beads were from Bio-Rad, and nickelnitrilotriacetic acid-agarose resin was from Qiagen. Tryptone and yeast
extract were from Difco. All other chemicals were reagent grade and
purchased from either Sigma or Mallinckrodt.
Plasmid Construction—The E. coli msbA gene was amplified from
W3110 genomic DNA by PCR with Pfu turbo (Stratagene) according to
the manufacturer’s instructions. The forward primer was 5⬘-ATG CTG
GTT TTT CAT ATG CAT AAC GAC-3⬘ (NdeI site underlined), and the
reverse primer was 5⬘-CGG GAT CCT CGA GTC ATT GGC CAA ACT
GCA TTT TG-3⬘ (BamHI site underlined). The msbA initiation and
termination codons in the primers are italicized. These primers were
used at a final concentration of 2.5 ng/l in a 100-l PCR mixture

containing 100 ng of genomic DNA and 5 units of Pfu polymerase. The
reaction conditions were as follows: a 94 °C denaturation for 1 min
followed by 25 cycles of 94 °C (denature) for 1 min, 55 °C (anneal) for 1
min, and 72 °C (extension) for 2 min. This was followed by a 10-min
runoff at 72 °C. The gel-purified PCR product was digested with NdeI
and BamHI (New England Biolabs) and ligated into an NdeI/BamHIdigested and shrimp alkaline phosphatase (Roche Molecular Biochemicals)-treated pET28b vector (Novagen) to give vector pWTD1. Vector
pWTD7, containing the temperature-sensitive MsbA allele (A270T),
was constructed in an identical manner starting from genomic DNA
from strain WD2 (11). Vector pWTD3 was constructed by cloning the
XbaI/HindIII fragment of pWTD1 (containing the in-frame hexahistidine tag and ribosomal binding site) into an XbaI/HindIII and shrimp
alkaline phosphatase-treated vector pACYC184 (New England Biolabs). All plasmids were sequenced at the Duke University sequencing
facility and found to be free of errors. Genomic DNA was prepared using
the Easy-DNA kit from Invitrogen.
Overexpression of N-His6-MsbA—pWTD1 was transformed into Novablue (DE3) cells (Novagen). A single kanamycin-resistant colony was
inoculated into 5 ml of LB broth (24) (adjusted to pH 7.0 and containing
30 g/ml kanamycin) and grown at 37 °C overnight. The overnight
culture was diluted 100-fold into 500 ml of LB broth containing kanamycin, and the cells were grown at 37 °C until A600 reached 0.6. Isopropyl-1-thio-␤-D-galactopyranoside was then added to a final concentration of 1 mM. Growth was continued at 30 °C for 3 h, and cells were
harvested by centrifugation at 6,000 ⫻ g for 15 min. All subsequent
steps were carried out at 0 – 4 °C. Cell pellets were resuspended in 50 ml
of 50 mM HEPES buffer, pH 7.5, containing 5 mM ␤-mercaptoethanol
and were broken by passage through a French pressure cell at 18,000
p.s.i. The crude lysate was cleared by centrifugation at 10,000 ⫻ g for 20
min. Membranes were prepared by two sequential ultracentrifugation
steps at 100,000 ⫻ g for 60 min with a wash of the first membrane pellet
in 10 ml of 50 mM HEPES buffer, pH 7.5, 500 mM NaCl, 5 mM MgCl2,
10% glycerol, and 5 mM ␤-mercaptoethanol (buffer A). The final membrane pellet was homogenized in buffer A at a protein concentration of
⬃5 mg/ml.
Solubilization and Purification of N-His6-MsbA—LDAO was added
to the washed membranes (5 mg/ml in buffer A) to a final concentration
of 2% (w/v) and incubated with rotation for 1 h at 4 °C. Insoluble
material was removed by ultracentrifugation at 125,000 ⫻ g for 1 h. The
soluble fraction was adjusted to 10 mM imidazole and loaded onto
a preequilibrated nickel-nitrilotriacetic acid-agarose column. After
washes with 5 column volumes of 10 mM and then with 5 column
volumes of 50 mM imidazole in buffer A containing 0.1% DDM, protein
was eluted with 5 column volumes of 200 mM imidazole in buffer A
containing 0.1% DDM.
Reconstitution of Purified N-His6-MsbA—For reconstitution of the
purified protein, E. coli phospholipids (polar lipid extract, Avanti) were
dried under a stream of nitrogen and then subjected to sonic irradiation
for 5 min in a bath sonicator at a concentration of 25 mg/ml in 50 mM
HEPES, pH 7.5, containing 50 mM NaCl, 5 mM MgCl2, and 2 mM
␤-mercaptoethanol. The liposomes were frozen on dry ice, thawed
slowly at room temperature, and then homogenized by five passages
through a 27-gauge needle. The liposomes were diluted to a concentration of 4 mg/ml in the above buffer, and DDM was added to solubilize
the system to generate mixed micelles (1 mol of DDM/mg of lipid).
Solubilization was followed spectrophotometrically at 540 nm (25). Purified N-His6-MsbA was added to the lipid/DDM mixed micelles at a
protein:lipid ratio of 1:100 (w/w). The mixture was incubated with
gentle agitation at room temperature for 30 min. Bio-Beads (previously
washed extensively with methanol and then water) were added at 80
mg/ml. The system was incubated for 2 h at 4 °C and then for 2 h and
for 16 h at 4 °C after the addition of fresh Bio-Beads. The final proteoliposomes were isolated by ultracentrifugation at 125,000 ⫻ g for 1 h at
4 °C. They were resuspended at 0.25 mg of protein/ml in buffer A
containing 1 mM dithiothreitol instead of ␤-mercaptoethanol and stored
at ⫺80 °C. All ATPase assays were carried out using proteoliposomes
that had undergone a freeze/thaw step and had been passed through a
27-gauge needle several times.
ATPase Assay—Purified MsbA protein in 0.1% DDM or reconstituted
into vesicles was assayed for ATPase activity at a protein concentration
of ⬃1–10 g/ml in a 150-l reaction mixture containing (final concentrations) 50 mM HEPES, adjusted to pH 7.5 with NaOH, 10 mM MgCl2,
1 mM dithiothreitol, and 2 mM ATP. In assays containing 0.1% DDM,
10% glycerol was also included. If exogenous lipids or inhibitors were
included in the assay, a 15-min preincubation of all components on ice
was included before the incubation at 37 °C. ATPase reactions were
incubated for the indicated times at 37 °C and stopped by the addition
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TABLE I
Relevant strains and plasmids
Strain or plasmid

E. coli
W3110
WD2
XL1-Blue MR
NovaBlue (DE3)
Plasmid
pET28b
pACYC184
pWTD1
pWTD3
pWTD7

Description

Source or reference

Wild type, F⫺, ⫺
W3110, aroA::Tn10 msbA2 (A270T)
⌬mcrABC recA1 endA1 gyrA96 relA1 supE44 thi-1 lac
⌬(srl-recA)306::Tn10(DE3) Tetr

E. coli Genetic Stock
Center, Yale
University
11
Stratagene
Novagen

Expression vector; T7lac promoter, Kanr
Low copy vector. Tetr Camr
pET28b containing wild type E. coli msbA (NdeI/BamHI sites)
XbaI/HindIII fragment of pWTD1 cloned into pACYC184
pET28b containing msbA2 of WD2 (NdeI/BamHI sites)

Novagen
New England Biolabs
This work
This work
This work

of 150 l of 12% SDS. The amounts of Pi released were determined by
a colorimetric method, as described by Gonzalez-Romo et al. (26), using
potassium phosphate as the standard. After the addition of SDS, 300 l
of a solution containing equal volumes of 12% ascorbic acid in 1 M HCl
and 2% ammonium molybdate in 1 M HCl was added, and the samples
were incubated at room temperature for 5 min. This was followed by the
addition of 450 l of an aqueous solution of 2% sodium citrate, 2%
sodium metaarsenite, and 2% acetic acid. After a 20-min incubation at
room temperature, absorbance was measured at 850 nm. The assay was
linear in the range of 6 – 400 M Pi.
Isolation of Kdo2-Lipid A—WBB06 cells (27) were grown overnight at
37 °C to A600 ⬃3.5 in 2 liters of LB broth adjusted to pH 7.0 and
supplemented with 12 g/ml tetracycline. Cells were harvested by
centrifugation at 6,000 ⫻ g for 10 min, washed with an equal volume of
phosphate-buffered saline (28), and resuspended in 160 ml of phosphate-buffered saline. Chloroform and methanol were added to give a
single-phase Bligh-Dyer mixture consisting of chloroform:methanol:
phosphate-buffered saline (1:2:0.8, v/v) (29). The cells were extracted for
1 h at room temperature with frequent mixing. Insoluble material was
removed by centrifugation at 3,000 ⫻ g for 10 min, and the supernatant,
containing the glycerophospholipids and Kdo2-lipid A, was removed. It
was converted to a two-phase Bligh-Dyer system by the addition of
chloroform and water to give the mixture chloroform:methanol:water
(2:2:1.8, v/v) (29). After thorough mixing, the phases were separated by
centrifugation as described above, and the upper phase was washed
with a fresh, preequilibrated Bligh-Dyer lower phase. The lower phases
were pooled, washed once with a fresh, preequilibrated Bligh-Dyer
upper phase, and dried in a rotary evaporator. The dried lipids were
redissolved in 10 ml of chloroform:methanol:water (2:3:1, v/v) and applied to a 2-ml DEAE-cellulose column (Whatman DE52), equilibrated
as the acetate form in the same solvent mixture (30, 31). The column
was washed with 2 column volumes of chloroform:methanol:water (2:
3:1, v/v) and eluted with 5 column volumes each of chloroform:methanol:aqueous ammonium acetate (at 60, 120, 240, 360, or 480 mM)
(2:3:1, v/v) (31) while collecting 2-ml fractions throughout the elution.
Phosphatidylethanolamine was not bound to the column, whereas phosphatidylglycerol and other phospholipids eluted in the 60 –120 mM
fractions. The Kdo2-lipid A 1,4⬘-bis-phosphate species eluted in the 240
mM fraction, but the Kdo2-lipid A 1-pyrophosphate variant (32, 33)
eluted in the 360 mM fractions. The fractions containing the purified
Kdo2-lipid A 1,4⬘-bis-phosphate were pooled and converted to a neutral
two-phase Bligh-Dyer system by the addition of appropriate amounts of
chloroform and water. The lower phase was neutralized with a few
drops of pyridine and was dried under a stream of nitrogen. It was then
resuspended with sonic irradiation for 2 min in a bath apparatus in 20
mM HEPES, pH 7.5, and stored at ⫺80 °C. The elution of the various
lipids from the DEAE column was monitored by spotting ⬃5-l samples
onto Silica Gel 60 TLC plates followed by development in a solvent
containing chloroform, pyridine, 88% formic acid, and water (50:50:
16:5, v/v), and visualization by sulfuric acid charring. The amount of
purified lipid was quantified by complete acid hydrolysis in 50 l of 5 M
HCl at 100 °C for 16 h followed by measurement of the released Pi,
using the phosphate assay described above (26). Potassium phosphate
samples were run in parallel to generate a standard curve. The final
yield of Kdo2-lipid A 1,4⬘-bis-phosphate was ⬃5 mg from 2 liters of cells.
The Kdo2-lipid A from strain WBB06 was greater than 95% pure as
judged by TLC analysis followed by sulfuric acid charring, and by
matrix-assisted laser desorption ionization time-of-flight mass spectrometry (data not shown).
Lipid X was isolated from E. coli MN7 (34) as described by Radika

and Raetz (35). Lipid IVA was prepared according to the procedure of
Garrett et al. (36) and was a gift from Dr. Stephen Trent of this
laboratory. RaLPS (3) was purchased from Sigma and suspended at a
concentration of 1 mM (molecular weight ⬃4,000) in 20 mM HEPES, pH
7.5. Free hexaacylated lipid A was prepared by pH 4.5 hydrolysis at
100 °C from either RaLPS or Kdo2-lipid A (10), and quantified by
phosphate assay as described above. All lipids suspended in aqueous
buffers were dispersed before use by sonic irradiation for 1 min in a
bath sonicator.
Analytical Methods—Protein samples were denatured at 100 °C for 5
min and analyzed by 12% SDS-PAGE followed by Coomassie staining.
Prestained low range standards from Bio-Rad were used to estimate
protein molecular weights. Protein concentrations were determined
with the Coomassie Plus Protein Assay Reagent (Pierce) using bovine
serum albumin as the standard.
RESULTS

Overexpression and Purification of E. coli MsbA—To facilitate purification, the E. coli msbA gene was cloned into pET28b
behind the T7 promoter in-frame with an N-terminal His6 tag.
This expression plasmid was designated pWTD1 (Table I). The
His-tagged protein, when expressed on the low copy vector
pWTD3 (a pACYC184 derivative), was functional as judged by
its ability to complement the growth at 44 °C of the MsbA
temperature-sensitive mutant WD2 (data not shown).
Membranes prepared from cells overexpressing msbA on
pWTD1 contained large amounts of a protein migrating at a
molecular mass of ⬃65 kDa which was absent in cells harboring pET28b (Fig. 2). The His-tagged MsbA fusion protein was
solubilized efficiently from membranes using 2% LDAO and
was purified by nickel affinity chromatography (Fig. 2). During
chromatography the detergent was changed to DDM. The protein was greater than 95% pure as judged by SDS-PAGE and
Coomassie Blue staining (Fig. 2). A typical preparation yielded
⬃3 mg of purified MsbA protein from 30 mg of washed
membranes.
ATPase Activity of Detergent-solubilized, Purified MsbA in
the Presence or Absence of Added Lipids—Using a colorimetric
assay for released Pi (26), we found that the ATPase specific
activity of the purified, detergent-solubilized MsbA was low,
typically in the range of 2– 4 nmol/min/mg (Fig. 3, top panel).
The addition of E. coli phospholipids to the assay system at
concentrations above 2 mg/ml greatly stimulated and stabilized
the ATPase activity (Fig. 3, middle panel). Phospholipids at 2
mg/ml or above would be expected to form vesicles, even in the
presence of 0.1% (1 mg/ml) DDM. However, the addition of
Kdo2-lipid A at low micromolar concentrations also resulted in
stimulation of ATPase activity (Fig. 3, bottom panel). At this
relatively low concentration the lipid should form mixed micelles with the nonionic detergent (37).
ATPase Activity Associated with Purified, Liposome-reconstituted MsbA—In light of the results shown in Fig. 3, we routinely reconstituted the solubilized MsbA protein into liposomes at a protein:lipid ratio of 1:100 (w/w). Proteoliposomes
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FIG. 2. Overexpression and purification of E. coli MsbA. The
sizes of the molecular mass standards (lane M) are indicated to the left
of the gel. Lane 1, membranes (10 g) from Novablue (DE3)/pET28
vector control cells; lane 2, membranes (10 g) from Novablue (DE3)/
pWTD1 cells; lane 3, 100,000 ⫻ g supernatant after solubilization of
membranes with 2% LDAO (applied in a volume equal to that in lane 2);
lane 4, MsbA protein eluted from the nickel column (5 g); lane 5,
reconstituted purified MsbA protein (5 g). After electrophoresis, the
gel was stained with 0.25% Coomassie Blue.

were prepared from E. coli phospholipids and purified MsbA,
both solubilized with DDM, followed by treatment with BioBeads to remove the detergent as described under “Experimental Procedures.” The MsbA-containing proteoliposomes were
found to have an intrinsic ATPase activity that was nearly
linear with time at 37 °C for 2 h, and with a protein concentration up to at least 2 g/150 l of reaction mixture (Fig. 4, A
and B). Using 2 mM ATP, a magnesium ion concentration of 10
mM (Fig. 4C) and pH values ranging from 7 to 8.5 (data not
shown) were optimal. The Vmax of the reconstituted protein was
37 nmol/min/mg, and the apparent Km for ATP was 878 M
(Fig. 5). These parameters are in the same range as reported
for the ABC transporters cystic fibrosis transmembrane conductance regulator (CFTR), multidrug resistance protein 1
(MRP1), and rod photoreceptor-specific ABC transporter
(ABCR) (21, 22, 38, 39). Proteoliposomes prepared from mockpurified extracts of vector (pET28b)-containing control cells
were found to have a background activity that was indistinguishable from liposomes prepared in the absence of protein
(data not shown). Therefore, in the experiments shown in Figs.
4 and 5, reaction mixtures containing protein-free liposomes
were run in parallel with the MsbA-reconstituted liposomes
and subtracted as nonenzymatic ATPase blanks. In general
these no-protein controls represented less than 10% of the
activity seen with reconstituted MsbA (data not shown).
Additional Stimulation of MsbA ATPase Activity by Hexaacylated Lipid A—In view of the genetic evidence that MsbA might
function both as a phospholipid and as a lipid A transporter
(10, 11), we tested the effect of hexaacylated Kdo2-lipid A on the
ATPase activity of reconstituted MsbA in proteoliposomes.
Kdo2-lipid A isolated from a heptose-deficient mutant of E. coli
(27) was incubated at various concentrations either with protein-free control liposomes or with MsbA-containing proteoliposomes for 15 min at 0 °C immediately before the assay at
37 °C. The ATPase activity of MsbA increased as much as 5-fold
over the basal level seen in the absence of Kdo2-lipid A (Fig.
6A). Stimulation was half-maximal at ⬃21 M Kdo2-lipid A
(Fig. 6A). The data suggest that MsbA may interact with
hexaacylated lipid A more strongly than with E. coli glycerophospholipids, resulting in additional stimulation of ATPase
activity.

FIG. 3. ATPase activity of solubilized purified MsbA and its
stimulation by E. coli phospholipids or Kdo2-lipid A. Top panel,
purified protein (25 g/ml) was incubated in the presence of 2 mM ATP,
50 mM HEPES, pH 7.0, 10 mM MgCl2, 1 mM dithiothreitol, 0.1% DDM,
and 10% glycerol for various times at 37 °C, and the generation of Pi
was measured (26). Middle panel, E. coli phospholipids (Avanti) were
dried down under nitrogen and sonicated in aqueous buffer at a concentration of 25 mg/ml. Appropriate volumes were then added to the
ATPase assay system described above to achieve the indicated final
concentrations of lipid. Incubations were carried out in the presence or
absence of added protein (25 g/ml) for 45 min. The generation of Pi was
measured (26), and the background from the protein-free controls was
subtracted for each point. Bottom panel, Kdo2-lipid A was added to the
ATPase assay system described above in the presence or absence of
MsbA protein (25 g/ml), and the incubation was carried out at 37 °C
for 45 min. All values are the averages of triplicate determinations
shown with standard deviations.

To investigate the structural specificity of the observed stimulation, MsbA proteoliposomes were preincubated with other
LPS preparations or with lipid A precursors, each at ⬃100 M,
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FIG. 5. Apparent Km and Vmax of purified MsbA for ATP and the
effect of 50 M Kdo2-lipid A. Proteoliposomes (1 g/150 l of reaction
mixture) were preincubated on ice for 15 min with 50 M Kdo2-lipid A
(squares) or without Kdo2-lipid A (circles) in standard assay buffer
containing the indicated concentrations of ATP (100 –3,000 M) immediately before incubation at 37 °C for 2 h. All values are the averages of
triplicate determinations shown with standard deviations. In A, apparent Km and Vmax values were determined using nonlinear least squares
fitting to the equation V ⫽ (Vmax[S])/(Km ⫹ [S]). Similar Km and Vmax
values were obtained from the Lineweaver-Burk plot (B).

FIG. 4. ATPase activity of MsbA reconstituted into proteoliposomes. A, proteoliposomes (containing 1 g of purified MsbA protein)
were incubated in a 150-l final volume consisting of 2 mM ATP, 50 mM
HEPES, pH 7.0, 10 mM MgCl2, and 1 mM dithiothreitol for various times
at 37 °C, and generation of Pi was measured (26). B, increasing amounts
of protein were incubated for 2 h at 37 °C in the above ATPase assay
mixture, and Pi generation was measured. C, proteoliposomes (1 g of
purified MsbA protein/150 l) were incubated in the standard ATPase
assay mixture with different amounts of MgCl2 at 37 °C, and Pi generation was measured. Control liposomes lacking protein were incubated
in parallel, and nonenzymatic Pi release was subtracted from the values
obtained in the presence of the MsbA-containing proteoliposomes. All
values are the averages of triplicate determinations shown with standard deviations.

as well as with phosphatidylcholine and cholesterol, which are
not made by E. coli. As illustrated in Fig. 6B, the precursors
lipid X and lipid IVA (Fig. 7) do not stimulate the ATPase
activity of MsbA above the levels achieved with glycerophospholipids alone. However, purified hexaacylated lipid A (lacking the Kdo region and other core sugars), obtained by pH 4.5

sodium acetate hydrolysis of LPS, also stimulates the ATPase
activity of MsbA above the level seen with reconstituted liposomes (Fig. 6B). Commercially available LPS from E. coli
EH100 (which contains hexaacylated lipid A and a complete
core domain but lacks O-antigen) likewise stimulates the
ATPase activity of MsbA (Fig. 6B) above the level seen with
glycerophospholipids. These observations are consistent with
previous reports that lipid A precursors are not transported to
the outer membrane as rapidly as hexaacylated lipid A is
(40, 41).
The Vmax for ATP calculated in the presence of 50 M Kdo2lipid A increased from 37 to 154 nmol/min/mg, whereas the Km
was decreased by more than half (Fig. 5). Effects of similar
magnitude were reported for the Vmax and Km of reconstituted
ABCR after preincubation with all-trans-retinal (21, 22). Taken
together with previous genetic studies (10, 11), these results
suggest that LPS species containing hexaacylated lipid A are
recognized the most effectively by MsbA, although glycerophospholipids are stimulatory as well. The MsbA assays described
in Figs. 3–7 should facilitate the search for specific small molecule inhibitors of MsbA, which might be useful as leads for
novel antibiotics.
The eukaryotic lipids cholesterol and phosphatidylcholine
have no effect in stimulating the MsbA ATPase above the
liposome background (Fig. 6B). In some mammalian tissues,
cholesterol efflux is mediated by the ABCA1 protein (42– 44),
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FIG. 7. Structures of lipid X, lipid IVA, and Kdo2-lipid A. The
roles of these substances as LPS precursors are well established (3, 5).

FIG. 6. Stimulation of MsbA ATPase activity in proteoliposomes by Kdo2-lipid A and related substances. A, proteoliposomes
(1 g/150 l of reaction mixture) or protein-free liposome controls were
preincubated on ice for 15 min with increasing concentrations of purified Kdo2-lipid A before a 2-h incubation at 37 °C in the standard
ATPase assay buffer. Pi release was measured (26), and values obtained
with appropriate blank liposomes were subtracted as background. B,
proteoliposomes (1 g/150 l of reaction mixture) or an equal volume of
protein-free liposomes was preincubated on ice for 15 min with 100 M
lipid A, various lipid A precursors, or other control lipids. Pi release was
assayed, and all values are the averages of triplicate determinations
shown with standard deviations. Stock solutions of lipid A precursors
were dispersed in 20 mM HEPES, pH 7.0, with sonic irradiation before
addition to the ATPase assay buffer. The lipids phosphatidylcholine and
cholesterol were dissolved in ethanol stock solutions at a concentration
of 10 mM and then diluted 1:100 into the ATPase assay buffer. Ethanol
controls were run in parallel and found not to inhibit or stimulate MsbA
ATPase activity.

an ABC transporter defective in Tangier disease (45– 47).
Additional Characterization of the MsbA ATPase Activity—
The effects on MsbA of known inhibitors or activators of previously characterized ABC transporters were assessed. Sodium
ortho-vanadate (or one of its oligomeric forms present in solution) is a potent inhibitor of the P-glycoprotein ATPase. Vanadate is thought to block the catalytic cycle by forming a noncovalent complex with MgADP at the ATPase site of the
transporter (48, 49). Vanadate inhibits the ATPase activity of
reconstituted MsbA by about 70%, with half-maximal inhibition observed at ⬃35 M (Fig. 8). In contrast, sodium azide, an
inhibitor of SecA and F-type ATPases (50), had no effect on
MsbA (data not shown). Substrates of Mdr1, like verapamil,
doxorubicin, vinblastine, daunomycin, or colchicines (16, 51),
likewise had no effect on the ATPase activity of MsbA (data not
shown).

FIG. 8. Inhibitory effect of vanadate on the ATPase activity of
MsbA. Proteoliposomes (1 g/150 l of reaction mixture) were preincubated on ice for 15 min with increasing amounts of sodium orthovanadate (10 –500 M) in the standard ATPase assay buffer before
incubation at 37 °C for 2 h. All Pi release values are the averages of
triplicate determinations shown with standard deviations.

Effect of the A270T Mutation on the ATPase Activity of
MsbA—The mutant WD2 contains a single amino acid substitution in MsbA (A270T) (Fig. 1B), which renders the cells
temperature-sensitive for growth (11). WD2 cells stop dividing
1 h after a shift from the permissive temperature of 30 °C to 42
or 44 °C (11). Growth inhibition is accompanied by the accumulation of newly made lipid A and glycerophospholipids in the
inner membrane (11). Concurrently, multiple inner membrane
folds and invaginations become visible by electron microscopy
(11).
MsbA (A270T) was amplified from WD2 genomic DNA, overexpressed, purified, and reconstituted in the same manner as
wild type MsbA. The basal ATPase specific activities of both the
wild type and mutant proteins were measured at 30 and 42 °C.
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FIG. 9. Reduced ATPase activity of reconstituted mutant
A270T MsbA at 42 °C. Proteoliposomes (1 g of purified MsbA protein/
150 l of reaction mixture), containing either wild type (circles) or
mutant A270T MsbA (squares), were incubated for increasing times in
the standard ATPase assay buffer at 30 °C (A) or at 42 °C (B). All Pi
release values are the averages of triplicate determinations shown with
standard deviations.

Interestingly, although both proteins had similar ATPase activities at 30 °C, the mutant activity was decreased significantly at 42 °C (Fig. 9). However, the -fold stimulation by
Kdo2-lipid A was similar for both proteins at both temperatures
(data not shown).
DISCUSSION

Previous studies from our laboratory have shown that depletion of cellular MsbA or the presence of a conditionally inactivating mutation in MsbA results in the loss of transport of lipid
A and glycerophospholipids from the cytoplasmic membrane to
the outer membrane (10, 11). These observations suggest that
MsbA functions either as a general lipid flippase, catalyzing
the transbilayer movement of lipids, or is involved in initiating
the transperiplasmic movement of LPS and phospholipids, or
both.
Our findings in E. coli support the idea of a more general
function for eukaryotic and other MDR-like proteins, to which
MsbA is closely related, in the transport of membrane lipids.
However, because the three major MDR proteins of animal
cells are not essential for cell growth (51) and because mutations do not result in a generalized lipid transport defect,
genetic approaches have not been very revealing so far. One
important exception is the Mdr2-deficient mouse, which is
characterized by a complete absence of phosphatidylcholine in
its bile, resulting in liver disease (52), suggesting that MDR2 is
a phosphatidylcholine-specific transporter in cells lining the
biliary tree. Another relevant example is the selective lipid
export function of the ABCA1 protein, which is defective in
Tangier disease (45– 47). Fibroblasts from patients with Tangier disease appear to have a defect in the export of cellular
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cholesterol and phospholipids from the plasma membrane to
circulating high density lipoproteins (53, 54).
The presence of dozens of additional uncharacterized membrane proteins that are related to the conventional MDRs in
animal cells may explain the lack of generalized lipid transport
phenotypes seen in the available MDR knockout mice. Some of
these additional MDR-like proteins may be able to catalyze
lipid transport reactions similar to those catalyzed by the major
MDR proteins (55), and they might function singly or in
combination.
Several ABC transporters of the MDR family have already
been shown to possess intrinsic ATPase activity that is stimulated in the presence of transported substrates. The best example is the mammalian Mdr1 (P-glycoprotein), which possesses an ATPase activity that is stimulated 3– 4-fold by
various drugs that it is known to transport, including doxorubicin and vinblastine (17, 19). Similarly, the ABCR protein has
an ATPase activity that is stimulated 3– 4-fold by all-transretinal and N-retinylidene-phosphatidylethanolamine (21, 22).
ATPase activity has also been reported for the transporter
associated with antigen processing (TAP), which is stimulated
by peptides (23).
In an effort to study the biochemistry of E. coli MsbA, we
have now purified and reconstituted the protein and have characterized its ATPase activity for the first time. The pure protein, when reconstituted with E. coli phospholipids, possesses
apparent Km and Vmax values for ATP which are similar to
those reported for several other purified ABC transporters
(21, 22, 38, 39). Interestingly, micromolar concentrations of
hexaacylated lipid A, Kdo2-lipid A, and LPS with an intact core
stimulate the basal ATPase activity above the level achieved by
glycerophospholipids alone. This stimulation appears to be specific because it is not seen with the same concentrations of lipid
X or lipid IVA. The latter are lipid A precursors (Fig. 7) that
contain either two or four acyl chains (5, 31, 56, 57), and they
are transported to the outer membrane less efficiently than is
hexaacylated lipid A (40, 41).
Our prior studies have shown that all phospholipids and
lipid A are retained in the inner membrane after the loss of
function of MsbA (10, 11). In the present work, detergentsolubilized MsbA exhibited a low basal ATPase activity that
was greatly stimulated by the addition of phospholipids (Fig.
3). When MsbA was reconstituted into proteoliposomes of
E. coli phospholipids in the absence of lipid A, significant
ATPase activity was likewise observed (Fig. 4). However, when
lipid A was added to these proteoliposomes, a large increase in
ATPase activity was seen (Figs. 5 and 6). These data are
consistent with the hypothesis that MsbA is both a phospholipid and a lipid A pump which couples ATP hydrolysis to lipid
efflux. MsbA may bind to lipid A more effectively than to
glycerophospholipids because of the additional intermolecular
contacts that could be achieved with a hexaacylated versus a
diacylated lipid. In wild type cells, the entire core domain
would be attached to lipid A prior to flip-flop (2, 3), and its
presence would have to be accommodated by MsbA.
Recent experiments designed to study phospholipid flip-flop
in bacterial membranes and model liposomes have suggested
that this process might be energy-independent in bacteria (58,
59). In model membranes, lipid flip-flop occurs at near physiological rates in the absence of ATP or a proton motive force,
provided that synthetic membrane-spanning peptides are reconstituted together with the lipids (60). These findings would
appear to be at odds with the our results from mutant WD2, in
which lipid transport is arrested at the nonpermissive temperature despite the presence of a normal complement of inner
membrane proteins (11). One explanation might be that MsbA
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uses energy from ATP hydrolysis to pump lipids from the outer
face of the inner membrane to the outer membrane while
facilitating generalized lipid flip-flop in an energy-independent
manner (Fig. 1A). Alternatively, extrapolations from studies
with isolated or reconstituted membranes may not adequately
recapitulate the intracellular environment.
The recent x-ray structure of MsbA (18) demonstrates that
the protein forms a homodimer (Fig. 1B). The dimer contains a
cleft, facing the cytoplasm in the available structure (18),
through which newly synthesized lipids might pass before export (Fig. 1B). A conformational change caused by lipid binding
to the membrane-embedded portion of the cleft (Fig. 1B) might
be coupled to ATP hydrolysis and transport or vice versa. This
model is consistent with our biochemical data (Figs. 3– 6) as
well as with studies of other MDR proteins. The A270T mutation in WD2 appears to lie near the periplasmic interface of the
two monomers (Fig. 1B). One might speculate that MsbA
(A270T) cannot form functional dimers at the nonpermissive
temperature or that the dimer interface cannot open to expel
newly made lipids on the periplasmic surface of the inner
membrane.
The availability of purified, catalytically active MsbA lays
the groundwork for additional functional studies. If MsbA is
indeed a general lipid flippase, as the crystal structure suggests (Fig. 1B) (18), this activity might be detectable in proteoliposomes. LPS or phospholipids could be labeled with fluorescent reporter groups and incorporated into proteoliposomes.
MsbA could be then tested for its ability to stimulate the loss of
quenchable fluorescence by impermeant reagents (60), indicative of flip-flop. This kind of approach was utilized to demonstrate lipid flippase activity of the ABC transporter LmrA of
L. lactis (61). However, LmrA is not required for growth in its
native setting (62),2 perhaps because of the presence of additional LmrA-like proteins in Lactococcus (63).
We have been unable to make E. coli cells resistant to several
antibiotics, including streptomycin, novobiocin, or erythromycin, following overexpression of MsbA from either low or high
copy vectors (data not shown). These observations, coupled
with the fact that msbA mutations are not known to be associated with generalized antibiotic resistance phenotypes in
E. coli (17), support the notion that E. coli MsbA functions
primarily to transport lipid A and glycerophospholipids.
If MsbA is part of a larger molecular machine catalyzing the
transperiplasmic movement of phospholipids and LPS, its
transport activity might be detectable only in the presence of
acceptor vesicles and selected outer membrane and periplasmic
proteins. A biochemical assay of this kind might actually lead
to the identification and purification of the relevant additional
protein components of the transport machinery (Fig. 1A). This
general strategy has been very successful in the characterization of the LolA-LolE system, which is responsible for transporting bacterial lipoproteins across the periplasm of Gramnegative bacteria (64).
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